Compare · PLSE vs SYK
PLSE vs SYK
Side-by-side comparison of Pulse Biosciences Inc (PLSE) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PLSE and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $108.02B, about 32.7x PLSE ($3.30B).
- Over the past year, PLSE is up 156.6% and SYK is down 20.5% - PLSE leads by 177.1 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 7 for PLSE).
- SYK has more recent analyst coverage (25 ratings vs 8 for PLSE).
- Company
- Pulse Biosciences Inc
- Stryker Corporation
- Price
- $45.65-1.31%
- $293.33+4.14%
- Market cap
- $3.30B
- $108.02B
- 1M return
- -7.84%
- +3.00%
- 1Y return
- +156.58%
- -20.53%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 7
- 8
- Recent ratings
- 8
- 25
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PLSE
- SEC Form 8-K filed by Pulse Biosciences Inc
- Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
- SEC Form 8-K filed by Pulse Biosciences Inc
- Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
- BTIG Research initiated coverage on Pulse Biosciences with a new price target
- SEC Form 424B5 filed by Pulse Biosciences Inc
- Pulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)